Safety and tolerability of BMS-986015 given in combination with BMS-936558 as measured by incidence of adverse events Approximately up to 27 months [clinicaltrials_resource:71fdbcc74e99adafd7df19b388e4da60]
Every 8 weeks during the Treatment Period (Cycle 1 Day 1 through Cycle 12 Day 56), and once during clinical follow-up
RECIST = Response Evaluation Criteria In Solid Tumors
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Safety and tolerability of BMS-986015 given in combination with BMS-936558 as measured by incidence of adverse events Approximately up to 27 months [clinicaltrials_resource:71fdbcc74e99adafd7df19b388e4da60]
Every 8 weeks during the Treatment Period (Cycle 1 Day 1 through Cycle 12 Day 56), and once during clinical follow-up
RECIST = Response Evaluation Criteria In Solid Tumors
Bio2RDF identifier
71fdbcc74e99adafd7df19b388e4da60
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:71fdbcc74e99adafd7df19b388e4da60
measure [clinicaltrials_vocabulary:measure]
Safety and tolerability of BMS ...... by incidence of adverse events
time frame [clinicaltrials_vocabulary:time-frame]
Approximately up to 27 months
description
Every 8 weeks during the Treat ...... ation Criteria In Solid Tumors
identifier
clinicaltrials_resource:71fdbcc74e99adafd7df19b388e4da60
title
Safety and tolerability of BMS ...... Approximately up to 27 months
@en
type
label
Safety and tolerability of BMS ...... dbcc74e99adafd7df19b388e4da60]
@en